Satellos Bioscience Inc.

Satellos Bioscience Inc. held its annual meeting of shareholders virtually on June 17, 2026. Shareholders elected all nine director nominees to hold office until the next annual meeting. Additionally, PricewaterhouseCoopers LLP was appointed as the company's auditor, with directors authorized to fix its remuneration. Approximately 55.33% of the company's issued and outstanding shares were represented at the meeting.

Satellos Bioscience Inc. announced the results of its Annual Meeting of Shareholders held on June 17, 2026. All nominees listed in the management information circular were successfully elected as directors, with shareholder participation at 55.3% of issued and outstanding common shares. Additionally, shareholders voted in favor of re-appointing PricewaterhouseCoopers LLP as the company's auditors.

Satellos Bioscience Inc. announced its participation in two investor conferences in June 2026. The company will present at the Jefferies Global Healthcare Conference on June 4 and join a panel at the Oppenheimer CNS & Neuro-Muscular Summit on June 10. Members of the leadership team will also be available for one-on-one investor meetings, and the presentation will be webcast live with a replay available afterward. Satellos is a clinical-stage drug development company focused on SAT-3247 for degenerative muscle diseases like DMD.

Satellos Bioscience Inc. announced that its management team will participate in two investor conferences in June. The company will attend the Jefferies Global Healthcare Conference on June 4, 2026, delivering a presentation. Additionally, Satellos will participate in the Oppenheimer CNS & Neuro-Muscular Summit on June 10, joining a panel discussion. Webcasts of the presentations will be available, and management will hold one-on-one investor meetings.

Satellos Bioscience Inc. announced its Annual General Meeting (AGM) of shareholders will be held virtually on June 17, 2026, at 1:00 p.m. Toronto time. Shareholders will vote on the election of nine directors, the appointment of PricewaterhouseCoopers LLP as auditors, and receive the audited financial statements for the year ended December 31, 2025. The Board recommends voting in favor of all resolutions, and the record date for voting is May 12, 2026.

Satellos Bioscience reported a net loss of $9.77 million for Q1 2026, an increase from $6.14 million in Q1 2025, driven by higher R&D and G&A expenses. The company successfully completed a public offering in February 2026, raising $57.2 million in gross proceeds, extending its cash runway through 2027. Clinical progress includes 11 active sites for the BASECAMP Phase 2 pediatric study, on track for Q3 2026 enrollment completion, and the initiation of the TRAILHEAD study in the U.S.

Satellos Bioscience reported a net loss of $9.8 million for Q1 2026, an increase from $6.1 million in Q1 2025, primarily due to higher R&D expenses for clinical activities. The company successfully raised $57 million through an equity offering in February 2026, boosting its cash and equivalents to $69.9 million and providing a financial runway through 2027. Operationally, Satellos made significant progress in its Phase 2 clinical trials for SAT-3247, with 11 active sites for the BASECAMP pediatric study and enrollment on track for Q3 2026, while also initiating the TRAILHEAD adult study in the U.S.